Shopping Cart
Remove All
Your shopping cart is currently empty
Daxdilimab
(Synonyms: VIB7734, MEDI7734) Copy Product Info
🥰Excellent
Synonyms: VIB7734, MEDI7734
Catalog No. T76767 Copy Product Info
Purity: 95%
🥰Excellent
Daxdilimab is a fully human monoclonal antibody targeting ILT7 (LILRA4), which is specifically expressed on plasmacytoid dendritic cells (pDCs). Daxdilimab depletes pDCs in circulation and tissues by inducing ADCC. As pDCs are the primary source of Type 1 interferons (IFN-I), this antibody effectively reduces IFN-I production and suppresses interferon-inducible gene signatures, serving as a tool for researching autoimmune diseases like SLE, dermatomyositis, and Sjögren's syndrome.
Daxdilimab
Cas No. 2245966-28-1
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $163 | - | In Stock | |
| 5 mg | $428 | - | In Stock | |
| 10 mg | $689 | - | In Stock | |
| 25 mg | $1,280 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Daxdilimab is a fully human monoclonal antibody targeting ILT7 (LILRA4), which is specifically expressed on plasmacytoid dendritic cells (pDCs). Daxdilimab depletes pDCs in circulation and tissues by inducing ADCC. As pDCs are the primary source of Type 1 interferons (IFN-I), this antibody effectively reduces IFN-I production and suppresses interferon-inducible gene signatures, serving as a tool for researching autoimmune diseases like SLE, dermatomyositis, and Sjögren's syndrome. |
| In vitro | In biochemical assays, Daxdilimab binds to ILT7 on human pDCs. Functional assays show the antibody induces ADCC-mediated depletion of pDCs in PBMCs, leading to a significant reduction in IFN-alpha secretion following TLR agonist stimulation [1][2]. |
| In vivo | In humanized mouse or non-human primate models, systemic Daxdilimab (1-10 mg/kg) triggers rapid and sustained depletion of pDCs in blood and skin, significantly reducing the expression of interferon-stimulated genes (ISGs) [2]. |
| Synonyms | VIB7734, MEDI7734 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | IL-T7 |
| Cas No. | 2245966-28-1 |
| Isotype | IgG1-REM |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Daxdilimab in vivo | Daxdilimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.